Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

The quantitative Gleason score improves prostate cancer risk assessment.

Reese AC, Cowan JE, Brajtbord JS, Harris CR, Carroll PR, Cooperberg MR.

Cancer. 2012 Dec 15;118(24):6046-54. doi: 10.1002/cncr.27670. Epub 2012 Jun 6.

2.

Prostatectomy pathology findings in an active surveillance population.

Ramirez-Backhaus M, Iborra I, Gomez-Ferrer A, Rubio-Briones J.

Arch Esp Urol. 2014 Jun;67(5):431-9. Review. English, Spanish.

PMID:
24914842
3.

What Are the Predictive Factors for Gleason Score Upgrade following RP?

Alchin DR, Murphy D, Lawrentschuk N.

Urol Int. 2016;96(1):1-4. doi: 10.1159/000439139. Epub 2015 Aug 29. Review.

PMID:
26314299
4.

Gleason 6 Prostate Cancer: Translating Biology into Population Health.

Eggener SE, Badani K, Barocas DA, Barrisford GW, Cheng JS, Chin AI, Corcoran A, Epstein JI, George AK, Gupta GN, Hayn MH, Kauffman EC, Lane B, Liss MA, Mirza M, Morgan TM, Moses K, Nepple KG, Preston MA, Rais-Bahrami S, Resnick MJ, Siddiqui MM, Silberstein J, Singer EA, Sonn GA, Sprenkle P, Stratton KL, Taylor J, Tomaszewski J, Tollefson M, Vickers A, White WM, Lowrance WT.

J Urol. 2015 Sep;194(3):626-34. doi: 10.1016/j.juro.2015.01.126. Epub 2015 Apr 4. Review.

5.

Grading of Prostate Cancer: Past, Present, and Future.

Matoso A, Epstein JI.

Curr Urol Rep. 2016 Mar;17(3):25. doi: 10.1007/s11934-016-0576-4. Review.

PMID:
26874537
6.
7.

A concise update on prostate pathology.

Xu W, Zhou M.

Cesk Patol. 2014;50(4):120-8. Review.

PMID:
25418898
8.

Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics.

Moschini M, Spahn M, Mattei A, Cheville J, Karnes RJ.

BMC Med. 2016 Apr 4;14:67. doi: 10.1186/s12916-016-0613-7. Review.

9.

Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.

Ross AE, D'Amico AV, Freedland SJ.

Prostate Cancer Prostatic Dis. 2016 Mar;19(1):1-6. doi: 10.1038/pcan.2015.31. Epub 2015 Jun 30. Review.

PMID:
26123120
10.

Gleason Score 6 - Prostate Cancer or Benign Variant?

Kn├╝chel R.

Oncol Res Treat. 2015;38(12):629-32. doi: 10.1159/000441735. Epub 2015 Nov 12. Review.

PMID:
26633167
12.

[From Gleason score to Ann Arbor staging- a selective choice of important scores and staging systems in oncology].

Greuter S.

Ther Umsch. 2013 Oct;70(10):607-11. doi: 10.1024/0040-5930/a000454. Review. German.

PMID:
24091341
13.

Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease.

Reichard CA, Klein EA.

Nat Rev Urol. 2017 Jan;14(1):59-64. doi: 10.1038/nrurol.2016.240. Epub 2016 Nov 29. Review.

PMID:
27898099
14.

Does true Gleason pattern 3 merit its cancer descriptor?

Miah S, Ahmed HU, Freeman A, Emberton M.

Nat Rev Urol. 2016 Sep;13(9):541-8. doi: 10.1038/nrurol.2016.141. Epub 2016 Aug 17. Review.

PMID:
27530265

Supplemental Content

Support Center